Advances in BK Virus Complications in Organ Transplantation and Beyond

• Main Authors: Abraham Cohen-Bucay, Silvia E. Ramirez-Andrade, Craig E. Gordon, Jean M. Francis, Vipul C. Chitalia
• Format: Article
• Language: English
• Published: Elsevier 2020-11-01
• Series: Kidney Medicine
• Subjects: BK virus, transplantation
• Online Access: http://www.sciencedirect.com/science/article/pii/S2590059520302053

Reactivation of BK virus (BKV) remains a dreaded complication in immunosuppressed states. Conventionally, BKV is known as a cause for BKV-associated nephropathy and allograft dysfunction in kidney transplant recipients. However, emerging studies have shown its negative impact on native kidney function and patient survival in other transplants and its potential role in diseases such as cancer. Because BKV-associated nephropathy is driven by immunosuppression, reduction in the latter is a convenient standard of care. However, this strategy is risk prone due to the development of donor-specific antibodies affecting long-term allograft survival. Despite its pathogenic role, there is a distinct lack of effective anti-BKV therapeutics. This limitation combined with increased morbidity and health care cost of BKV-associated diseases add to the complexity of BKV management. While summarizing recent advances in the pathogenesis of BKV-associated nephropathy and its reactivation in other organ transplants, this review illustrates the limitations of current and emerging therapeutic options and provides a compelling argument for an effective targeted anti-BKV drug.